Kris V. Kowdley

65.1k citations

451 papers · 29.4k indexed · 18 hit papers · h-index 86

Epidemiology top 0.01%
Hepatology top 0.01%
Surgery top 0.2%
Endocrinology, Diabetes and Metabolism top 0.1%
Molecular Biology top 2%

Co-authors: Arun J. Sanyal David E. Kleiner Brent A. Neuschwander‐Tetri Elizabeth M. Brunt Naga Chalasani Mark L. Van Natta Joel E. Lavine Arthur J. McCullough
Topics: Liver Disease Diagnosis and Treatment (244 papers)Hepatitis C virus research (114 papers)Liver Diseases and Immunity (99 papers)
Cited by: Hepatology Epidemiology Endocrinology, Diabetes and Metabolism
Journals: New England Journal of Medicine The Lancet Nature Medicine
Partner nations: United States Canada United Kingdom

In The Last Decade

Kris V. Kowdley

432 papers receiving 28.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

2010 2.5k citations Arun J. Sanyal, Naga Chalasani et al. profile →
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

2014 1.7k citations Brent A. Neuschwander‐Tetri, Rohit Loomba et al. profile →
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

2014 686 citations Kris V. Kowdley et al. profile →
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease

2021 646 citations Arun J. Sanyal, Brent A. Neuschwander‐Tetri et al. profile →
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

2014 646 citations Kris V. Kowdley, Kosh Agarwal et al. profile →
Endpoints and clinical trial design for nonalcoholic steatohepatitis

2011 586 citations Arun J. Sanyal, Kris V. Kowdley et al. Hepatology profile →
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial

2004 545 citations Keith D. Lindor, Kris V. Kowdley et al. Hepatology profile →
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis #

2009 478 citations Keith D. Lindor, Kris V. Kowdley et al. Hepatology profile →
Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease

2018 452 citations Kris V. Kowdley, Brent A. Neuschwander‐Tetri et al. profile →
Diagnosis and management of hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases

2011 428 citations Bruce R. Bacon, Kris V. Kowdley et al. Hepatology profile →
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid

2014 421 citations Gideon M. Hirschfield, Andrew L. Mason et al. Gastroenterology profile →
Serum Ferritin Is An Independent Predictor of Histologic Severity and Advanced Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

2011 412 citations Kris V. Kowdley, Laura Wilson et al. Hepatology profile →
ACG Clinical Guideline: Primary Sclerosing Cholangitis

2015 331 citations Keith D. Lindor, Kris V. Kowdley et al. profile →
Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study

2020 280 citations Vlad Ratziu, Arun J. Sanyal et al. Hepatology profile →
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH

2023 271 citations Rohit Loomba, Arun J. Sanyal et al. profile →
Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease

2019 270 citations Laura Wilson, Naga Chalasani et al. profile →
Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial

2021 261 citations Mazen Noureddin, Kris V. Kowdley et al. Hepatology profile →
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis

2019 205 citations Michael Trauner, Aliya Gulamhusein et al. Hepatology profile →

Peers

Countries citing papers authored by Kris V. Kowdley

Since Specialization

Citations

This map shows the geographic impact of Kris V. Kowdley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kris V. Kowdley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kris V. Kowdley more than expected).

Fields of papers citing papers by Kris V. Kowdley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kris V. Kowdley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kris V. Kowdley. The network helps show where Kris V. Kowdley may publish in the future.

Co-authorship network of co-authors of Kris V. Kowdley

This figure shows the co-authorship network connecting the top 25 collaborators of Kris V. Kowdley. A scholar is included among the top collaborators of Kris V. Kowdley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kris V. Kowdley. Kris V. Kowdley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view 2026 ·Nature Reviews Gastroenterology & Hepatology ·(unknown),Robert Mitchell-Thain,(unknown),Jessica Dyson,(unknown),Bo Mølholm Hansen,(unknown),Kris V. Kowdley,(unknown),Andreas E. Kremer,Marlyn J. Mayo,M.G. Swain,(unknown),(unknown),(unknown),(unknown),Andrew D. Yeoman,(unknown),(unknown)	0
2	Treatment Persistence, Normal Alkaline Phosphatase and Clinical Outcomes in Primary Biliary Cholangitis 2025 ·Alimentary Pharmacology & Therapeutics ·Kris V. Kowdley,(unknown),Yi Pan,Mihail Samnaliev,(unknown),Carla Perez	0
3	Association of HFE genotypes with hemochromatosis-related phenotypes in the All of Us research program 2025 ·Genetics in Medicine Open ·(unknown),Ramal Moonesinghe,Lu Shi,(unknown),Gail P. Jarvik,Kris V. Kowdley,Laura A. Schieve,Scott D. Grosse,W. David Dotson,Muin J. Khoury	0
4	PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease 2024 ·Hepatology ·Naga Chalasani,Eduardo Vilar‐Gómez,Rohit Loomba,Katherine P. Yates,Anna Mae Diehl,Brent A. Neuschwander‐Tetri,Srinivasan Dasarathy,Kris V. Kowdley,Norah A. Terrault,Laura Wilson,James Tonascia,Arun J. Sanyal	18
5	Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitis 2024 ·BMJ Open ·Nasir Hussain,Christopher Ma,Gideon M. Hirschfield,Martine Walmsley,(unknown),Mette Vesterhus,Kris V. Kowdley,Annika Bergquist,Cyriel Y. Ponsioen,Cynthia Levy,David N. Assis,(unknown),Christopher L. Bowlus,Michael Trauner,Olalekan Lee Aiyegbusi,Vipul Jairath,Palak Trivedi	3
6	PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis 2023 ·BMC Gastroenterology ·Michael Trauner,Chuhan Chung,(unknown),Xiangyu Liu,Xiaomin Lu,Jun Xu,Clare M. Tempany,Zachary Goodman,Martti Färkkilâ,Atsushi Tanaka,Palak Trivedi,Kris V. Kowdley,Christopher L. Bowlus,Cynthia Levy,Robert P. Myers	14
7	Impact of COVID-19 pandemic on alcohol-related hepatitis admissions: Analysis of nationwide data 2016-2020 2023 ·The American Journal of the Medical Sciences ·Aalam Sohal,(unknown),Jay Patel,(unknown),(unknown),(unknown),Marina Roytman,Kris V. Kowdley	6
8	Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study 2023 ·Hepatology Communications ·Arun J. Sanyal,Rohit Loomba,Quentin M. Anstee,Vlad Ratziu,Kris V. Kowdley,Mary E. Rinella,Stephen Harrison,Murray B. Resnick,(unknown),Sangeeta Sawhney,(unknown),Zobair M. Younossi	7
9	Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis 2023 ·Alimentary Pharmacology & Therapeutics ·Stephen A. Harrison,Vlad Ratziu,Quentin M. Anstee,Mazen Noureddin,Arun J. Sanyal,Jörn M. Schattenberg,Pierre Bédossa,Mustafa R. Bashir,David J. Schneider,Rebecca Taub,Meena B. Bansal,Kris V. Kowdley,Zobair M. Younossi,Rohit Loomba	56
10	EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study 2021 ·Journal of Hepatology ·Vlad Ratziu,Mary E. Rinella,Brent A. Neuschwander‐Tetri,Eric Lawitz,Douglas Denham,Zeid Kayali,Aasim Sheikh,Kris V. Kowdley,Taddese Desta,Magdy Elkhashab,(unknown),Bryan Goodwin,Alaa Ahmad,Nathalie Adda	87
11	An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign‐Born Persons Living in the United States 2021 ·Hepatology ·Robert J. Wong,Carol Brosgart,(unknown),(unknown),Mark Chen,Chari Cohen,W. Ray Kim,Kris V. Kowdley,Anna S. Lok,Naoky Tsai,John Ward,(unknown),Robert G. Gish	93
12	Current and potential treatments for primary biliary cholangitis 2019 ·The Lancet. Gastroenterology & hepatology ·(unknown),Kris V. Kowdley	69
13	The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC. 2019 ·Hepatology ·Michael Trauner,Aliya Gulamhusein,Bilal Hameed,Stephen H. Caldwell,Mitchell L. Shiffman,Charles Landis,Bertus Eksteen,Kosh Agarwal,Andrew J. Muir,Simon Rushbrook,Xiaomin Lu,Jun Xu,Jen‐Chieh Chuang,Andrew N. Billin,Chuhan Chung,Georgia Li,G. Mani Subramanian,Robert P. Myers,Christopher L. Bowlus,Kris V. Kowdley	3
14	Effectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients 2017 ·Alimentary Pharmacology & Therapeutics ·Michael P. Curry,Elliot B. Tapper,Bruce R. Bacon,Douglas T. Dieterich,Steven L. Flamm,(unknown),Kris V. Kowdley,(unknown),Scott Milligan,(unknown),Zobair M. Younossi,Nezam H. Afdhal	30
15	Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD) 2016 ·Medicine ·Ratree Sawangjit,Bunchai Chongmelaxme,Pochamana Phisalprapa,Surasak Saokaew,Ammarin Thakkinstian,Kris V. Kowdley,Nathorn Chaiyakunapruk	50
16	Ulcerative Colitis–Associated Colorectal Cancer Arises in a Field of Short Telomeres, Senescence, and Inflammation 2011 ·Cancer Research ·Rosa Ana Risques,Lisa A. Lai,Çiğdem Himmetoğlu,Anoosheh Ebaee,Lin Li,Ziding Feng,Mary P. Bronner,(unknown),Kris V. Kowdley,Keith D. Lindor,Peter S. Rabinovitch,Teresa A. Brentnall	118
17	28 AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID AS MONOTHERAPY IN PBC 2011 ·Journal of Hepatology ·Kris V. Kowdley,(unknown),Velimir A. Luketic,Robert Chapman,A.K. Burroughs,Gideon M. Hirschfield,Raoul Poupon,Christoph Schramm,(unknown),C Rust,Albert Parés,Andrew L. Mason,(unknown),(unknown),O. Böhm,Erin Castelloe,Mark Pruzanski,Д. А. Шапиро	47
18	HFE-associated hereditary hemochromatosis 2009 ·Genetics in Medicine ·Jacob Alexander,Kris V. Kowdley	81
19	Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ). 2003 ·Gastroenterology ·Marion G. Peters,Hie‐Won Hann,Paul Martin,E. Jenny Heathcote,Peter Buggisch,R Rubin,Marc Bourlière,Kris V. Kowdley,Christian Trépo,DF Gray,Mark Sullivan,K. Kleber,Ramin Ebrahimi,S. Xiong,Carol Brosgart	440
20	Prophylactic colectomy or surveillance for chronic ulcerative colitis? A decision analysis 1995 ·Gastroenterology ·Dawn Provenzale,Kris V. Kowdley,Sanjeev Arora,John B. Wong	74

About Kris V. Kowdley

Kris V. Kowdley is a scholar working on Hepatology, Epidemiology and Hematology, having authored 451 papers that have together received 29.4k indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (244 papers), Hepatitis C virus research (114 papers) and Liver Diseases and Immunity (99 papers). The work is most often cited by research in Hepatology (14.5k citations), Epidemiology (20.1k citations) and Endocrinology, Diabetes and Metabolism (5.1k citations). Kris V. Kowdley has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Arun J. Sanyal, David E. Kleiner, Brent A. Neuschwander‐Tetri, Elizabeth M. Brunt, Naga Chalasani, Mark L. Van Natta, Joel E. Lavine, Arthur J. McCullough, Jeanne M. Clark and Anna Mae Diehl. Their work appears in journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact